These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10888033)

  • 1. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
    Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
    Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
    Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
    Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
    El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
    Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies.
    Saishin Y; Saishin Y; Takahashi K; Seo MS; Melia M; Campochiaro PA
    Invest Ophthalmol Vis Sci; 2003 Aug; 44(8):3656-62. PubMed ID: 12882820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
    Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
    Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.
    Fabbro D; Buchdunger E; Wood J; Mestan J; Hofmann F; Ferrari S; Mett H; O'Reilly T; Meyer T
    Pharmacol Ther; 1999; 82(2-3):293-301. PubMed ID: 10454207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice.
    Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
    Anticancer Res; 2003; 23(2B):1395-9. PubMed ID: 12820400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells.
    Yoshikawa N; Nakamura K; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
    Life Sci; 2003 Feb; 72(12):1377-87. PubMed ID: 12527035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
    Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
    Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
    Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
    Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
    Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PKCalpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412.
    Kawamoto T; Akisue T; Kishimoto K; Hara H; Imabori M; Fujimoto T; Kurosaka M; Hitora T; Kawaguchi Y; Yamamoto T
    Anticancer Res; 2008; 28(2A):825-32. PubMed ID: 18507025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier.
    Saishin Y; Saishin Y; Takahashi K; Melia M; Vinores SA; Campochiaro PA
    J Cell Physiol; 2003 May; 195(2):210-9. PubMed ID: 12652648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts.
    Nakazono-Kusaba A; Takahashi-Yanaga F; Miwa Y; Morimoto S; Furue M; Sasaguri T
    Eur J Pharmacol; 2004 Aug; 497(2):155-60. PubMed ID: 15306200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
    Ozaki H; Seo MS; Ozaki K; Yamada H; Yamada E; Okamoto N; Hofmann F; Wood JM; Campochiaro PA
    Am J Pathol; 2000 Feb; 156(2):697-707. PubMed ID: 10666398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.